Flagship explainer
What drives Monte Rosa Therapeutics, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$38.6M | FY2025 |
| |
| Income before tax | −$39.7M | FY2025 |
|
| Operating income | −$54.2M | FY2025 |
|
| $124M | FY2025 |
| |
| Ending assets | $449M | FY2025 |
|
| Beginning assets | $439M | FY2024 |
|
| $233M | FY2025 |
| |
| $223M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001193125-26-109360